Developer docs
API playgroundTry for free, no card

Search company profiles

OPTIMIZERx

Full company profile

uuid00026ic

Namestring
OPTIMIZERx
Legal namestring
OptimizeRx Corporation
Websiteurl
optimizerx.com
Company typeenum
Public
Founded yearint
2015
Descriptiontext

OptimizeRx Corporation (NASDAQ: OPRX) is a public healthcare marketing technology company that operates a Dynamic Audience Activation Platform (DAAP) for pharmaceutical brands, life sciences companies, and healthcare agencies. The company synchronizes healthcare practitioner (HCP) and direct-to-consumer (DTC) marketing by combining an authenticated electronic health record (EHR) network, Micro-Neighborhood® ZIP+4-level disease prevalence targeting, and AI/ML models that identify patient eligibility windows and predict care moments. Its customer base is concentrated in enterprise pharma — oncology, rare disease, sleep disorders, ulcerative colitis, and other specialty therapy brands — served through direct enterprise field sales and agency partner channels.

The platform's technical core combines real-world clinical data, predictive machine learning on diagnosis/procedure/lab codes, and a patent-pending Natural Language Audience Builder (NLAB) that enables DSP-integrated audience creation using natural-language prompts. OptimizeRx delivers messaging across EHR, connected TV (CTV), addressable TV, audio, online video, social, programmatic display, email, direct mail, out-of-home (via Lamar Advertising), pharmacy alerts, refill alerts, and financial messaging channels. The platform is SOC 2 Type II and ISO 27001 certified, NAI-aligned, and integrated with DeepIntent as the first DSP to access its authenticated EHR network (Q3 2026).

OptimizeRx generates revenue through subscription and usage-based arrangements with pharmaceutical and life sciences clients, with contract values tied to campaign scope, audience size, channel mix, and duration. The company reports FY2025 revenue of $109.4 million with $24.3 million of adjusted EBITDA (Rule-of-40 achieved), Q4 2025 revenue of $32.2 million, and FY2026 guidance of $109-$114 million — lowered approximately 13% from prior expectations, citing Most Favored Nation pricing uncertainty and softer pharma budgets. The acquisition of Medicx Health in October 2023 for $95 million remains the most significant inorganic move, and the company announced a $10 million share repurchase program in late 2025/early 2026.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersWaltham, United States
HQ citystring
Waltham
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
healthcare marketing technology, pharmaceutical marketing platform, EHR network advertising, point-of-care messaging, omnichannel HCP marketing
Industry1 code
PRIMARYHLALAKAD
EHR/EMR Integration & Interoperability Middleware (HL7/FHIR)
Healthcare & Life Sciences/Telehealth Platforms/Telehealth Infrastructure & Enablement Platforms (video, scheduling, EHR integration)
NAICS code2 codes
  • Computer Systems Design Services541512
  • Computer Systems Design and Related Services54151
SIC code1 code
  • Services-Prepackaged Software7372
Product category
Healthcare Marketing Technology
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Healthcare Marketing Platform (Subscription/Usage)
TypeSubscription Recurring
Description

OptimizeRx generates revenue through a combination of subscription and usage-based arrangements with pharmaceutical and life sciences companies. Revenue is driven by access to its EHR network, programmatic audience activation, and omnichannel marketing services. The company reports revenue from point-of-care messaging, programmatic display, and synchronized HCP+DTC marketing campaigns.

globenewswire.com
2Technology Platform Licensing
TypeSubscription Recurring
Description

Revenue from technology platform access, including AI-powered audience building tools (NLAB) and authenticated EHR network integration. The company positions NLAB as a new recurring revenue stream through bundling with authenticated point-of-care inventory for DSP integrations.

finance.yahoo.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

OptimizeRx provides an AI-powered Dynamic Audience Activation Platform (DAAP) that uses real-world health data and machine learning to identify patient and healthcare provider audiences for pharmaceutical marketing. The platform combines a proprietary authenticated EHR network, patented Micro-Neighborhood targeting, and the Natural Language Audience Builder (NLAB) to deliver synchronized HCP and DTC campaigns across programmatic, CTV, EHR, audio, social, out-of-home, and other channels.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 33% total script lift for oncology brand using integrated EHR and social media strategy
+5 more records
Product overview1 text field

OptimizeRx is a healthcare marketing technology company offering a unified omnichannel platform for life sciences marketing. The core offering centers on the Dynamic Audience Activation Platform (DAAP), which uses AI and real-world clinical data to identify and activate target patient and healthcare provider audiences. Key platform components include the proprietary Authenticated EHR Network enabling point-of-care messaging, Micro-Neighborhood® Targeting for geographic-clinical precision targeting, and the newly launched Natural Language Audience Builder (NLAB) for natural language-based audience building. The Synchronized Marketing module coordinates HCP and DTC channel strategies. The platform supports delivery across multiple channels including programmatic, social media, connected TV (CTV), audio, online video, email, out-of-home advertising, direct mail, addressable TV, pharmacy alerts, refill alerts, financial messaging, and health system targeting.

Product and service5 records
1Dynamic Audience Activation Platform (DAAP)
CategoryHealthcare Marketing Platform
Description

AI-powered platform that uses machine learning and real-world clinical data to identify, profile, and activate target patient and healthcare provider audiences across multiple channels for omnichannel pharmaceutical marketing, sold to pharmaceutical brands and life sciences companies.

2Authenticated EHR Network
CategoryPoint-of-Care Advertising Network
Description

Proprietary network of authenticated electronic health record integrations enabling point-of-care advertising and engagement within healthcare provider clinical workflows at clinically relevant decision moments, sold to pharmaceutical brands, agencies, and DSP partners.

3Point-of-Care Network
CategoryPoint-of-Care Advertising Network
Description

Digital network spanning electronic health record systems, pharmacy systems, and health systems enabling pharmaceutical messaging at point-of-care including EHR messaging, pharmacy alerts, and refill alerts, sold to pharmaceutical brands.

4Natural Language Audience Builder (NLAB)
CategoryAI Audience Building Tool
Description

Patent-pending AI-powered tool for demand-side platforms and agency media planning that enables life sciences marketers to build and manage custom HCP audiences using natural language prompts without requiring code or analyst support, sold to DSPs and agencies.

5Micro-Neighborhood Targeting
Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-05-21
Description

DeepIntent, the leading healthcare demand-side platform, became the first DSP to integrate OptimizeRx's proprietary authenticated EHR network into its advertising platform. The integration enables life sciences marketers to programmatically activate advertising within HCP workflows at clinically relevant decision moments using a privacy-safe solution. The authenticated EHR network is expected to be available on the DeepIntent platform in Q3 2026.

Strategic tierMinorTypeOthersAnnounced on2026-04-08
Description

Mary Varghese Presti, Corporate Vice President and COO of Microsoft's Health & Life Sciences division, was appointed to OptimizeRx's board of directors, bringing technology and operational expertise from Microsoft to the company's governance.

3Lamar Advertising
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-09-09
Description

Strategic partnership combining OptimizeRx's patented Micro-Neighborhood® Targeting data with Lamar's nationwide out-of-home advertising inventory. Enables pharmaceutical brands to reach clinically relevant patient populations based on disease prevalence data by mapping Lamar's inventory at the ZIP+4 level to OptimizeRx's clinical data. Positions out-of-home advertising as measurable and data-driven for life sciences brands.

markets.financialcontent.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-10-25
Description

OptimizeRx completed its acquisition of Medicx Health, a healthcare consumer-focused marketing and analytics company, for $95 million. The acquisition expanded OptimizeRx's omnichannel healthcare marketing platform and increased revenue run rate to nearly $100 million. Full organizational integration was expected in early 2024, with Steve Silvestro promoted to President and Theresa Greco appointed as Chief Commercial Officer as part of the transition.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Professional network for U.S. physicians with a pharma marketing platform for HCP-targeted messaging. Comparable in serving pharmaceutical advertisers seeking access to clinicians, though distribution is owned-network rather than EHR-workflow based.

TypeEmerging player
Description

Healthcare commercial intelligence and provider data platform used for HCP targeting and life sciences sales/marketing. Adjacent to OptimizeRx's audience-building use cases, particularly for NPI-level HCP targeting, but does not provide EHR-workflow ad delivery.

TypeBroad incumbent
Description

Global healthcare data, analytics, and technology company with a large pharma commercial solutions business. Overlaps with OptimizeRx in real-world data-driven audience targeting, media activation, and pharma marketing measurement at much larger scale.

TypeDirect peer
Description

Point-of-care patient engagement network inside physician offices and digital health platforms. Direct competitor in the point-of-care messaging and HCP+DTC synchronization categories where OptimizeRx competes.

TypeDirect peer
Description

Point-of-care health media platform delivering content and advertising in exam rooms and through digital endpoints. Competes with OptimizeRx for pharma point-of-care budgets, though focused on physical/office touchpoints vs EHR workflow.

TypeDirect peer
Description

Healthcare-focused demand-side platform (DSP) that programmatically buys health and pharma advertising. Direct counterpart to OptimizeRx on the buy side; also an integration partner after becoming the first DSP to plug into OptimizeRx's authenticated EHR network.

TypeDirect peer
Description

Privacy-safe audience targeting and HCP/DTC activation for life sciences brands. Overlaps directly with OptimizeRx on real-world data-driven audience building and omnichannel pharma campaigns.

TypeBroad incumbent
Description

Cloud software for life sciences, including CRM, data, and commercial solutions used by most large pharma manufacturers. A broad incumbent whose commercial and data products can substitute parts of the OptimizeRx stack in larger enterprise deals.

TypeDirect peer
Description

Programmatic ad-tech platform with a dedicated health vertical. Competes directly with OptimizeRx on HCP-targeted programmatic campaigns, audience activation, and healthcare publisher monetization.

10Crossix (Veeva)
TypeBroad incumbent
Description

Patient and HCP data analytics for life sciences marketing, now part of Veeva Systems. Provides comparable measurement and audience analytics that overlap with OptimizeRx's real-world evidence and audience activation capabilities, but within Veeva's broader commercial suite.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI capability9 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A4 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

OPTIMIZERx

Healthcare Marketing Technologyoptimizerx.com

What OPTIMIZERx does

OptimizeRx Corporation (NASDAQ: OPRX) is a public healthcare marketing technology company that operates a Dynamic Audience Activation Platform (DAAP) for pharmaceutical brands, life sciences companies, and healthcare agencies. The company synchronizes healthcare practitioner (HCP) and direct-to-consumer (DTC) marketing by combining an authenticated electronic health record (EHR) network, Micro-Neighborhood® ZIP+4-level disease prevalence targeting, and AI/ML models that identify patient eligibility windows and predict care moments. Its customer base is concentrated in enterprise pharma — oncology, rare disease, sleep disorders, ulcerative colitis, and other specialty therapy brands — served through direct enterprise field sales and agency partner channels.

The platform's technical core combines real-world clinical data, predictive machine learning on diagnosis/procedure/lab codes, and a patent-pending Natural Language Audience Builder (NLAB) that enables DSP-integrated audience creation using natural-language prompts. OptimizeRx delivers messaging across EHR, connected TV (CTV), addressable TV, audio, online video, social, programmatic display, email, direct mail, out-of-home (via Lamar Advertising), pharmacy alerts, refill alerts, and financial messaging channels. The platform is SOC 2 Type II and ISO 27001 certified, NAI-aligned, and integrated with DeepIntent as the first DSP to access its authenticated EHR network (Q3 2026).

OptimizeRx generates revenue through subscription and usage-based arrangements with pharmaceutical and life sciences clients, with contract values tied to campaign scope, audience size, channel mix, and duration. The company reports FY2025 revenue of $109.4 million with $24.3 million of adjusted EBITDA (Rule-of-40 achieved), Q4 2025 revenue of $32.2 million, and FY2026 guidance of $109-$114 million — lowered approximately 13% from prior expectations, citing Most Favored Nation pricing uncertainty and softer pharma budgets. The acquisition of Medicx Health in October 2023 for $95 million remains the most significant inorganic move, and the company announced a $10 million share repurchase program in late 2025/early 2026.

OPTIMIZERx firmographics

Firmographics
Name
OPTIMIZERx
Legal name
OptimizeRx Corporation
Website
https://optimizerx.com
Company type
Public
Founded year
2015
Operating status
Operating
Headcount range
101–250 employees
Ownership category
akta.pro rank

OPTIMIZERx industry classification

Industry
Product category
Healthcare Marketing Technology
NAICS
Computer Systems Design Services (541512), Computer Systems Design and Related Services (54151)
SIC
Services-Prepackaged Software (7372)
akta.pro industry
PRIMARYHLALAKAD
EHR/EMR Integration & Interoperability Middleware (HL7/FHIR)
Healthcare & Life Sciences/Telehealth Platforms/Telehealth Infrastructure & Enablement Platforms (video, scheduling, EHR integration)

Keywords

  • Healthcare marketing technology
  • Pharmaceutical marketing platform
  • EHR network advertising
  • Point-of-care messaging
  • Omnichannel HCP marketing

Where OPTIMIZERx is headquartered

Location

Headquarters

HQ city
Waltham
HQ country
United States
HQ region
North America

Offices1 record

Markets served

OPTIMIZERx business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations

Revenue model

  1. Healthcare Marketing Platform (Subscription/Usage): OptimizeRx generates revenue through a combination of subscription and usage-based arrangements with pharmaceutical and life sciences companies. Revenue is driven by access to its EHR network, programmatic audience activation, and omnichannel marketing services. The company reports revenue from point-of-care messaging, programmatic display, and synchronized HCP+DTC marketing campaigns.
  2. Technology Platform Licensing: Revenue from technology platform access, including AI-powered audience building tools (NLAB) and authenticated EHR network integration. The company positions NLAB as a new recurring revenue stream through bundling with authenticated point-of-care inventory for DSP integrations.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels7 records

OPTIMIZERx product offering

Product offering

Core offering

OptimizeRx provides an AI-powered Dynamic Audience Activation Platform (DAAP) that uses real-world health data and machine learning to identify patient and healthcare provider audiences for pharmaceutical marketing. The platform combines a proprietary authenticated EHR network, patented Micro-Neighborhood targeting, and the Natural Language Audience Builder (NLAB) to deliver synchronized HCP and DTC campaigns across programmatic, CTV, EHR, audio, social, out-of-home, and other channels.

Product overview

OptimizeRx is a healthcare marketing technology company offering a unified omnichannel platform for life sciences marketing. The core offering centers on the Dynamic Audience Activation Platform (DAAP), which uses AI and real-world clinical data to identify and activate target patient and healthcare provider audiences. Key platform components include the proprietary Authenticated EHR Network enabling point-of-care messaging, Micro-Neighborhood® Targeting for geographic-clinical precision targeting, and the newly launched Natural Language Audience Builder (NLAB) for natural language-based audience building. The Synchronized Marketing module coordinates HCP and DTC channel strategies. The platform supports delivery across multiple channels including programmatic, social media, connected TV (CTV), audio, online video, email, out-of-home advertising, direct mail, addressable TV, pharmacy alerts, refill alerts, financial messaging, and health system targeting.

Differentiator

Problem solved

Functional benefit

Products and services

  • Dynamic Audience Activation Platform (DAAP) AI-powered platform that uses machine learning and real-world clinical data to identify, profile, and activate target patient and healthcare provider audiences across multiple channels for omnichannel pharmaceutical marketing, sold to pharmaceutical brands and life sciences companies.
  • Authenticated EHR Network Proprietary network of authenticated electronic health record integrations enabling point-of-care advertising and engagement within healthcare provider clinical workflows at clinically relevant decision moments, sold to pharmaceutical brands, agencies, and DSP partners.
  • Point-of-Care Network Digital network spanning electronic health record systems, pharmacy systems, and health systems enabling pharmaceutical messaging at point-of-care including EHR messaging, pharmacy alerts, and refill alerts, sold to pharmaceutical brands.
  • Natural Language Audience Builder (NLAB) Patent-pending AI-powered tool for demand-side platforms and agency media planning that enables life sciences marketers to build and manage custom HCP audiences using natural language prompts without requiring code or analyst support, sold to DSPs and agencies.
  • Micro-Neighborhood Targeting

Quantifiable outcome

  • 33% total script lift for oncology brand using integrated EHR and social media strategy
  • +5 more outcomes

Companies that use OPTIMIZERx

Customer profile

Named customers4 records

Segments4 records

Ideal customer profiles2 records

OPTIMIZERx technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability9 records

Feature4 records

OPTIMIZERx partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and minor.

  • DeepIntentcoreTechnology or Integration · 21 May 2026DeepIntent, the leading healthcare demand-side platform, became the first DSP to integrate OptimizeRx's proprietary authenticated EHR network into its advertising platform. The integration enables life sciences marketers to programmatically activate advertising within HCP workflows at clinically relevant decision moments using a privacy-safe solution. The authenticated EHR network is expected to be available on the DeepIntent platform in Q3 2026.
  • Microsoft Health & Life SciencesminorOthers · 8 April 2026Mary Varghese Presti, Corporate Vice President and COO of Microsoft's Health & Life Sciences division, was appointed to OptimizeRx's board of directors, bringing technology and operational expertise from Microsoft to the company's governance.
  • Lamar AdvertisingcoreStrategic or Co-development Partner · 9 September 2025Strategic partnership combining OptimizeRx's patented Micro-Neighborhood® Targeting data with Lamar's nationwide out-of-home advertising inventory. Enables pharmaceutical brands to reach clinically relevant patient populations based on disease prevalence data by mapping Lamar's inventory at the ZIP+4 level to OptimizeRx's clinical data. Positions out-of-home advertising as measurable and data-driven for life sciences brands.
  • Medicx HealthcoreStrategic or Co-development Partner · 25 October 2023OptimizeRx completed its acquisition of Medicx Health, a healthcare consumer-focused marketing and analytics company, for $95 million. The acquisition expanded OptimizeRx's omnichannel healthcare marketing platform and increased revenue run rate to nearly $100 million. Full organizational integration was expected in early 2024, with Steve Silvestro promoted to President and Theresa Greco appointed as Chief Commercial Officer as part of the transition.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

OPTIMIZERx competitors and assessment

Company assessment

Direct peers

  • Doximity: Professional network for U.S. physicians with a pharma marketing platform for HCP-targeted messaging. Comparable in serving pharmaceutical advertisers seeking access to clinicians, though distribution is owned-network rather than EHR-workflow based.
  • PatientPoint: Point-of-care patient engagement network inside physician offices and digital health platforms. Direct competitor in the point-of-care messaging and HCP+DTC synchronization categories where OptimizeRx competes.
  • Outcome Health: Point-of-care health media platform delivering content and advertising in exam rooms and through digital endpoints. Competes with OptimizeRx for pharma point-of-care budgets, though focused on physical/office touchpoints vs EHR workflow.
  • DeepIntent: Healthcare-focused demand-side platform (DSP) that programmatically buys health and pharma advertising. Direct counterpart to OptimizeRx on the buy side; also an integration partner after becoming the first DSP to plug into OptimizeRx's authenticated EHR network.
  • Swoop: Privacy-safe audience targeting and HCP/DTC activation for life sciences brands. Overlaps directly with OptimizeRx on real-world data-driven audience building and omnichannel pharma campaigns.
  • PulsePoint: Programmatic ad-tech platform with a dedicated health vertical. Competes directly with OptimizeRx on HCP-targeted programmatic campaigns, audience activation, and healthcare publisher monetization.

Emerging players

  • Definitive Healthcare: Healthcare commercial intelligence and provider data platform used for HCP targeting and life sciences sales/marketing. Adjacent to OptimizeRx's audience-building use cases, particularly for NPI-level HCP targeting, but does not provide EHR-workflow ad delivery.

Broad incumbents

  • IQVIA: Global healthcare data, analytics, and technology company with a large pharma commercial solutions business. Overlaps with OptimizeRx in real-world data-driven audience targeting, media activation, and pharma marketing measurement at much larger scale.
  • Veeva Systems: Cloud software for life sciences, including CRM, data, and commercial solutions used by most large pharma manufacturers. A broad incumbent whose commercial and data products can substitute parts of the OptimizeRx stack in larger enterprise deals.
  • Crossix (Veeva): Patient and HCP data analytics for life sciences marketing, now part of Veeva Systems. Provides comparable measurement and audience analytics that overlap with OptimizeRx's real-world evidence and audience activation capabilities, but within Veeva's broader commercial suite.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

OPTIMIZERx social profiles

Digital presence

OPTIMIZERx compliance and trust

Trust signal

Compliance2 records

OPTIMIZERx financial estimates

Financial estimate

Revenue estimate

Valuation estimate

OPTIMIZERx leadership team

Management profile

Number of profiles

Profiles14 records

OPTIMIZERx subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

OPTIMIZERx funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

OPTIMIZERx M&A and investment

M&A and investment

M&A4 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about OPTIMIZERx

What does OPTIMIZERx do?

OptimizeRx provides an AI-powered Dynamic Audience Activation Platform (DAAP) that uses real-world health data and machine learning to identify patient and healthcare provider audiences for pharmaceutical marketing. The platform combines a proprietary authenticated EHR network, patented Micro-Neighborhood targeting, and the Natural Language Audience Builder (NLAB) to deliver synchronized HCP and DTC campaigns across programmatic, CTV, EHR, audio, social, out-of-home, and other channels.

Is OPTIMIZERx a public or private company?

OPTIMIZERx is a public company. It is classified as public and is currently operating.

When was OPTIMIZERx founded?

OPTIMIZERx was founded in 2015. It employs 101 to 250 people.

Where is OPTIMIZERx based?

OPTIMIZERx is headquartered in Waltham, United States, in the North America region.

How does OPTIMIZERx make money?

Two revenue lines are on record. Healthcare Marketing Platform (Subscription/Usage) is the primary driver. The others are technology Platform Licensing.

Who are OPTIMIZERx's main competitors?

Direct peers on record are Doximity, PatientPoint, Outcome Health, DeepIntent, Swoop and PulsePoint. Definitive Healthcare is listed as an emerging player. Broad incumbents are IQVIA, Veeva Systems and Crossix (Veeva).

Does OPTIMIZERx have an API?

No public API is recorded for OPTIMIZERx.

What industry is OPTIMIZERx in?

OPTIMIZERx's product category is Healthcare Marketing Technology. Its primary akta.pro industry code is HLALAKAD, EHR/EMR Integration & Interoperability Middleware (HL7/FHIR). Its NAICS code is 541512 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireOptimizeRx to Participate in the 15th Annual ROTH Technology ConferenceOptimizeRx Corp. announced that management will participate in the 15th Annual ROTH Technology Conference on November 18, 2026, in New York. The company, a healthcare technology provider, will be available for meetings or further details through institutional contacts.Simply Wall StOptimizeRx Fell 52%, But The Story Isn't OverOptimizeRx's stock fell 52% over the past year, with Q3 revenue dropping from $26.067m to $21.615m. The company integrated its EHR and e-prescribing inventory into PulsePoint, aiming to deepen clinician workflow. Analysts see a potential turnaround if DSP integrations and AI DAAP growth convert to higher-margin subscription revenue.TradingViewLake Street maintains OptimizeRx at Buy, lowers price target to $10 from $11Lake Street maintained OptimizeRx at Buy and lowered its price target to $10 from $11, a 9.1% decrease. The target implies an upside of 11.7% from the Nov 11 close of $8.95.YahooOptimizeRx Corp (OPRX) (Q3 2026) Earnings Call Highlights: Margin Expansion and Programmatic ...OptimizeRx reported Q3 2026 results with a 29% adjusted EBITDA margin and a 10% net revenue retention rate, citing a disrupted large client. The company is 20% below contracted revenue for 2026 but 20% ahead for 2027, with debt repayment ahead of schedule and a path to a 30% EBITDA margin.TradingViewOptimizeRx Corporation Stock 12‑Month Price Target Cut to $12.4, Implies 39% UpsideAnalysts' average price target for OptimizeRx Corporation fell to $12.4 from $12.6, implying about 39% upside from the Nov. 11 closing price. The consensus rating remains Buy across six analysts, with forecasts ranging from $11 to $18 per share.Seeking AlphaOptimizeRx Corporation (OPRX) Q3 2026 Earnings Call TranscriptOptimizeRx reported Q3 2026 revenue of $21.6 million and adjusted EBITDA of $6.3 million, both exceeding consensus. The company highlighted strong adjusted EBITDA performance, though revenue was only modestly ahead of expectations.Quiver QuantitativeOPTIMIZERX ($OPRX) Releases Q3 2026 Earnings | OPRX Stock NewsOPTIMIZERX reported Q3 2026 earnings of $0.20 per share, beating estimates of $0.18, and revenue of $21.62 million, exceeding estimates of $21.61 million. The stock fell 8.03% after market close. Hedge fund activity shows 42 institutions added shares while 82 reduced positions.BenzingaOptimizeRx Q3 2026 Earnings Call Transcript - OptimizeRx (NASDAQ:OPRX)OptimizeRx reported Q3 2026 revenue of $21.6 million and adjusted EBITDA of $6.3 million, both beating consensus despite a 17% year-over-year revenue decline. The company revised its full-year 2026 revenue guidance to $87–93 million, citing delayed customer spending, while maintaining adjusted EBITDA guidance of $21–25 million. Management sees renewed client spending and pent-up demand for 2027.MarketWatchOptimizeRx Shares Tumble on Cut to Outlook, Despite 3Q BeatOptimizeRx cut its full-year revenue outlook to $87-93 million after Q3 profit beat, sending shares down 21% in after-hours trading. Q3 revenue fell to $21.6 million from $26.1 million a year earlier, while adjusted EPS of 20 cents beat the 16-cent estimate.TradingViewOptimizeRx Q3 2026 Earnings Call Is LiveOptimizeRx's Q3 2026 earnings call is live, with executives discussing financial results and answering analyst questions. The call may include surprise news, and management commentary on demand, margins, or capital spending could move markets.